This custom array consisted of 41 cancer-specific antigens selected from the highest-reacting antigens for each ASC probe and nine benign disease-specific antigens (AURKA, CROCCP2, CTAG1A, MAGEA4, MAGEA9, PALM2, PMEPA1, SMYD5_frag and USP14) selected from the highest-reacting antigens in benign serum (and no reaction in healthy serum) on the high-density protein microarrays. This evidence concerns the gene CTAG1A and cancer.